These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11761222)

  • 21. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 22. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 23. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 24. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
    Varma P; Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
    [No Abstract]   [Full Text] [Related]  

  • 26. Dunkel proposals and the medical profession.
    Roy UK
    J Indian Med Assoc; 1993 Nov; 91(11):295-6. PubMed ID: 8138655
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the opportunities for pharmaceutical manufacturers in emerging markets.
    Anderson T; Olson J; Sobelman D
    J Manag Care Pharm; 2009 Jun; 15(5):396-402. PubMed ID: 19496636
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of India's new patents law 2005: a physician's perspective.
    Lele RD
    J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
    [No Abstract]   [Full Text] [Related]  

  • 29. Intellectual property and its role in the pharmaceutical industry.
    Atkinson JD; Jones R
    Future Med Chem; 2009 Dec; 1(9):1547-50. PubMed ID: 21425976
    [No Abstract]   [Full Text] [Related]  

  • 30. Fine print TRIPS up multinational and Indian companies.
    Frantz S
    Nat Rev Drug Discov; 2005 Feb; 4(2):94-5. PubMed ID: 15759327
    [No Abstract]   [Full Text] [Related]  

  • 31. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

  • 32. Bringing business risk into sharp focus.
    Gruber B; Walsh E
    Nat Biotechnol; 2012 Jan; 30(1):30-2. PubMed ID: 22231088
    [No Abstract]   [Full Text] [Related]  

  • 33. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 34. TRIPS-plus and access to medicines in China.
    Chen J; Nie X; Yao P; Shi L
    J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 36. An overview of pharmaceutical cocrystals as intellectual property.
    Trask AV
    Mol Pharm; 2007; 4(3):301-9. PubMed ID: 17477544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Essential AIDS medications in India.
    Thomas J
    Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
    [No Abstract]   [Full Text] [Related]  

  • 38. Science and the law. Working through the patent problem.
    Walsh JP; Cohen WM; Arora A
    Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
    [No Abstract]   [Full Text] [Related]  

  • 39. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
    Lipschitz Y; Tamir O; Shemer J
    Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.